The European Medicines Agency’s (EMA) Committee for Medicinal Products for Human Use (CHMP) recommends Novartis’ CAR T-cell therapy for follicular lymphoma
2022.3.1
The EMA has recommended granting European Commission (EC) approval to Novartis’ CAR T-cell therapy, Kymriah® (tisagenlecleucel), to treat adult relapsed or refractory (r/r) follicular lymphoma (FL) patients. In April 2020, the US Food and Drug Administration granted...